Abcam, ab318985, Anti-JAM-C antibody [EPR29224-576] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal JAM-C antibody. Carrier free. Suitable for Flow Cyt, ICC/IF, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR29224-576,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, ICC/IF, Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab318985 is the carrier-free version of
ab318984
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Junctional adhesion molecule-C (JAM-C) is a cell adhesion molecule belonging to the immunoglobulin superfamily also known as JAM3. It has a mass around 37 kDa. JAM-C is present on endothelial cells various immune cells and some epithelial cells. This protein functions mechanically in maintaining tight junctions that control paracellular permeability and are important in cell-to-cell interactions.
Biological function summary
Junctional adhesion molecule-C plays significant roles in leukocyte migration angiogenesis and the maintenance of vascular endothelial barrier function. JAM-C is part of a larger junctional adhesion molecule complex which includes JAM-A and JAM-B that collectively influence these processes. Its expression in tissues such as the heart and brain suggests specialized roles in physiological functions including cardiovascular regulation and CNS barriers.
Pathways
Junctional adhesion molecule-C is an integral component of the leukocyte transmigration and angiogenesis pathways. These pathways collaborate to allow immune cells to pass through vessel walls a fundamental process in immune surveillance and response. Additionally JAM-C interacts with integrins and other adhesion molecules facilitating cellular communication necessary for tissue repair and growth.
Dysregulation of junctional adhesion molecule-C expression associates with inflammatory diseases and cancer. Altered JAM-C levels have implications in autoimmune disorders where abnormal leukocyte extravasation occurs. Its connection to cancer involves interactions with proteins like VE-cadherin contributing to increased tumor angiogenesis and metastasis making it a potential target for therapeutic intervention in these conditions.